CSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact

Bulletin Express

08/05

CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license option for one of the pre-clinical candidate (PCC) programs covered by the strategic research collaboration signed on 13 June 2025.

Under the agreement, CSPC Pharma is responsible for discovering oral small-molecule PCCs targeting multiple disease areas, including immunological disorders. The latest milestone indicates that research and development activities are advancing as scheduled.

The collaboration grants AstraZeneca rights to develop, manufacture and commercialise licensed products arising from the selected PCCs. CSPC Pharma emphasised that future development, manufacturing and commercial outcomes remain subject to uncertainties and pledged to issue further announcements on any material developments.

Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities. The board of CSPC Pharma is chaired by Mr. Cai Dong Chen.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1173745599"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173745599\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173745599?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173745599","market":"hk","top_or_hot":-1,"title":"CSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license option for one of the pre-clinical candidate (PCC) programs covered by the strategic research collaboration signed on 13 June 2025.</p>\n<p>Under the agreement, CSPC Pharma is responsible for discovering oral small-molecule PCCs targeting multiple disease areas, including immunological disorders. The latest milestone indicates that research and development activities are advancing as scheduled.</p>\n<p>The collaboration grants AstraZeneca rights to develop, manufacture and commercialise licensed products arising from the selected PCCs. CSPC Pharma emphasised that future development, manufacturing and commercial outcomes remain subject to uncertainties and pledged to issue further announcements on any material developments.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities. The board of CSPC Pharma is chaired by Mr. Cai Dong Chen.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-05 18:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license option for one of the pre-clinical candidate (PCC) programs covered by the strategic research collaboration signed on 13 June 2025.</p>\n<p>Under the agreement, CSPC Pharma is responsible for discovering oral small-molecule PCCs targeting multiple disease areas, including immunological disorders. The latest milestone indicates that research and development activities are advancing as scheduled.</p>\n<p>The collaboration grants AstraZeneca rights to develop, manufacture and commercialise licensed products arising from the selected PCCs. CSPC Pharma emphasised that future development, manufacturing and commercial outcomes remain subject to uncertainties and pledged to issue further announcements on any material developments.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities. The board of CSPC Pharma is chaired by Mr. Cai Dong Chen.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1173745599","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173745599","pubTimestamp":1785924335,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团根据小分子研发协议从阿斯利康获得 1000 万美元里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license option for one of the pre-clinical candidate (PCC) programs covered by the strategic research collaboration signed on 13 June 2025.\nUnder the agreement, CSPC Pharma is responsible for discovering oral small-molecule PCCs targeting multiple disease areas, including immunological disorders. The latest milestone indicates that research and development activities are advancing as scheduled.\nThe collaboration grants AstraZeneca rights to develop, manufacture and commercialise licensed products arising from the selected PCCs. CSPC Pharma emphasised that future development, manufacturing and commercial outcomes remain subject to uncertainties and pledged to issue further announcements on any material developments.\nShareholders and potential investors are advised to exercise caution when dealing in the company’s securities. The board of CSPC Pharma is chaired by Mr. Cai Dong Chen.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}